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Background. NKG2D is an activating receptor expressed by NK and T cells, which have 
crucial functions in tumor and microbial immunosurveillance. Several cytokines have been 
identified as modulators of NKG2D receptor expression. However, little is known about 
NKG2D gene regulation. In this study, we found that microRNA 1245 attenuated the expression 
of NKG2D in NK cells.  
Design and Methods. We investigated the potential interactions between the 3’-untranslated 
region of NKG2D gene and microRNAs as well as their functional roles in the regulation of 
NKG2D expression and cytotoxicity in NK cells. 
Results.  TGF-β1, a major negative regulator of NKG2D expression, post-transcriptionally 
upregulated mature microRNA 1245 expression, thus downregulating NKG2D expression and 
impairing NKG2D-mediated immune responses in NK cells. Conversely, miR-1245 
downregulation significantly augmented the expression of NKG2D expression in NK cells, 
resulting in more efficient NKG2D-mediated cytotoxicity. 
Conclusions.  These results reveal a novel NKG2D regulatory pathway mediated by 
microRNA 1245, which may represent one of the mechanisms used by TGF-β1 to attenuate 
NKG2D expression in NK cells. 
DOI: 10.3324/haematol.2011.058529




NKG2D is an activating receptor expressed on NK cells that plays a pivotal role in tumor 
immunosurveillance1-4. NKG2D is a member of the type II C-type lectin-like family of 
transmembrane proteins that function as both an activating and co-stimulatory receptor and is 
constitutively expressed on most NK cells, as well on γδ T cells, some subsets of CD4+ and 
CD8+ T cells 5. The NKG2D receptor recognizes multiple and structurally different ligands 
(NKG2D-Ls), including the MHC class I-chain related proteins (MICA and MICB) and the 
UL-16 binding proteins (ULBP 1-6) 6. These ligands are either absent or poorly expressed in 
normal tissues but are upregulated in response to cellular stresses such as microbial infections 
and transformation 1, 5. Extensive research during the last few years has demonstrated the 
cytokine network that regulates the cell surface expression of the NKG2D receptor, however, 
little is known about the mechanisms that control NKG2D gene expression. The study focused 
on the potential interactions between the 3’-untranslated region (3’UTR) of NKG2D gene and 
microRNAs. microRNAs are endogenous, single stranded RNA strands that modulate gene 
expression by binding to complementary sites in the 3’UTR of the target gene’s mRNA. These 
17-22 base oligonucleotides mediate gene regulation by either directly inducing mRNA 
degradation or by decreasing translational efficiency 7, 8. The data presented herein identify 
microRNA (miR)-1245 as a novel negative regulator of NKG2D, and may clarify one of the 
mechanisms used by TGF-β1 to attenuate NKG2D expression. 
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Designs and methods 
Cell lines 
NK cell lines including NK-92 and KHYG-1 (a generous gift from Dr. Y. Isobe from Juntendo 
University Japan) and NKL, obtained from Dr. M. J. Robertson (Bone Marrow Transplantation 
Program, Indiana University, Indianapolis, IN) were cultured in IMDM supplemented with 20% 
FBS, 100 µg/ml streptomycin, 100 IU/ml penicillin and 100 IU/ml IL-2 (Millipore, Temecula, 
California. The NK cell line YT was kindly provided by Dr. H. Kanegane from Toyama 
University and they were cultured in RPMI 1640 + 20% FBS, 100 µg/ml streptomycin and 100 
U/ml of penicillin. The K562 cells transfected with the membrane-bound form of IL-15 and 
human 4-1BBL (K562-mb15-41BBL cells) were generously provided by Dr. Dario Campana 
(St. Jude Children's Research Hospital, Memphis TN.) and they were cultured in RPMI 1640 
supplemented with 10% FBS. The 293FT cells were purchased from Invitrogen and were 
maintained in D-MEM (high glucose) 10% FBS, 0.1 mM MEM Non-Essential Amino Acids, 6 
mM L-glutamine, 1 mM MEM Sodium Pyruvate 1% and 500 µg/ml of Geneticin (all from 
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NK cell preparation and cell culture  
Heparinized blood samples were collected from 24 healthy Japanese volunteers. The ages of the 
subjects (12 males and 10 females) ranged from 20 and 40 years (median 32 years). Peripheral 
blood mononuclear cells (PBMCs) were isolated using a lymphoprep (Pharmacia Biotech, 
Uppsala, Sweden) and the NK cell fraction was purified using the untouched NK isolation kit 
(Invitrogen) following the manufacturer’s recommendations. Flow cytometry confirmed that 
these cells were more than 95% CD3- CD56+ CD16+ NK cells. For some experiments NK cells 
were obtained by culturing the PBMCs from healthy donors in the presence of irradiated 
K562-mb15-41BBL cells in RPMI 1640 containing 10% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 100 IU/mL IL-2 for 10 days as described previously 9. These cultured PBMCs 
contained > 95% CD3-CD56+CD16+ NK cells and are referred to as “cultured NK cells”. This 
study was approved by the Ethics Committee of Kanazawa University. 
 
Flow cytometry  
The detection of CD3, CD56, CD16, CD160, MICA/B (BD Bioscience), NKG2D, NKp30, 
NKp44 and NKp46 (Beckman Coulter, Shizuoka, Japan) was performed by staining the cells 
with appropriate FITC- or PE-labeled mAbs (all from BD Bioscience). ULBP ligand detection 
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was performed by indirect staining using anti-ULBP1, ULBP2 and ULBP3 mAbs (R&D 
Biosystems), followed by staining with FITC-labeled anti-mouse IgG (BD Bioscience). Data 
acquisition and flow cytometry analyses were carried out on a BD FACS Calibur instrument 
using the CellQuest software package. The NKG2D expression level on NK cells from each 
individual was determined by the mean fluorescence intensity (MFI) calculated by subtracting 
the MFI in cells stained with the isotype antibody from the MFI in the corresponding cells 
stained with an anti-NKG2D Ab. 
 
Quantitation of NKG2D mRNA levels 
Total RNA was extracted from NK cells using Isogen (Nippon Gene, Tokyo, Japan) following 
the manufacturer’s instructions. Complementary DNA (cDNA) synthesis was carried out using 
the QuantiTect Reverse Transcription kit (Qiagen Inc. Hilden Germany). Amplification of 
cDNA was monitored using a QuantiFast SYBR green PCR kit (Qiagen) on a StepOne plus 
instrument (Applied Biosystems).  Predesigned specific primers for NKG2D (assay name 
Hs_KLRK1_1_SG, Qiagen) and a GAPDH primer kit (Search LC, Heidelberg, Germany) were 
used for mRNA quantification in each sample. The amount of NKG2D mRNA relative to 
GAPDH mRNA was calculated by the comparative CT method using the relative expression 
function included in the StepOne v2.2 software package (Applies Biosystems). 
DOI: 10.3324/haematol.2011.058529
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Measurement of microRNA  
To detect mature miR-1245, total RNA was extracted using the Isogen LS reagent (Nippon 
gene) and reverse transcription was performed using a TaqMan microRNA RT kit following the 
manufacturer’s recommendations (Applied Biosystems). The resultant cDNA was amplified 
using the TaqMan microRNA assays (hs-miR-1245, assay ID002823) with the TaqMan 
Universal PCR master mix II no UNG (Applied Biosystems). The PCR reactions and cycling 
parameters were set following the manufacturer’s recommendations with minor modifications 
as follow: a 10 µl PCR reaction contained 4.5 µl of diluted cDNA product, 1X TaqMan 
Universal master mix and 1X of the TaqMan microRNA assay or 1X of the U6b-specific 
TaqMan probe (hs-miR-U6B assay ID001093). The reactions were incubated in 96-wells plates 
at 95°C for 10 min, followed by 44 cycles of 95°C for 15 s and 58°C for 1 min. All reactions 
were run in duplicate in a StepOne plus RT-PCR system (Applied Biosystems). The data 
analysis was performed with the StepOne v2.2 software package (Applied Biosystems). The 
relative quantities of mature miR-1245 were calculated using the comparative CT method after 
normalization to the expression of U6b, as reported by others 10 11. 
 For the primary gene transcript of miR-1245 (pri-miR-1245) measurement, RNA was 
subjected to reverse transcription using a high capacity reverse transcription kit (Applied 
DOI: 10.3324/haematol.2011.058529
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Biosystems) according to the manufacturer’s instructions. Quantitative RT-PCR was performed 
using the TaqMan gene expression master mix (Applied Biosystems) with specific probes for 
pri-miR-1245 (Assay ID: Hs03305715_pri) and for human GAPDH (Applied Biosystems) in a 
StepOne plus RT-PCR system (Applied Biosystems). The relative levels pri-miR-1245 
normalized to GAPDH mRNA were calculated by the comparative CT method using the relative 
expression function included in the StepOne v2.2 software package (Applies Biosystems). 
 Some cells were cultured in the presence or absence of variable concentrations of one of 
the following recombinant cytokines TGF-β1, IL-15, IFNγ (PeproTech Inc,) or IL-2 and 
harvested at several time points for RNA extraction, and then were subjected to mature 
miR-1245 and pri-miR-1245 quantification. 
 
Exosome precipitation from human blood plasma and miRNA detection in exosomes 
EDTA-Blood was collected from healthy donors or from 10 patients with hematologic 
malignancies before starting chemotherapy. All patients gave their written informed consent to 
participate in molecular studies of this nature according to the declaration of Helsinki. A 
detailed description of the patients is shown in Table 1  (supplementary data). The samples 
were processed for plasma isolation immediately after collection. The isolated plasma was 
further centrifuged at 3,000 x g for 15 minutes to remove cell debris and subjected to exosome 
DOI: 10.3324/haematol.2011.058529
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precipitation using the ExoQuick exosome precipitation kit (System Biosciences) following the 
manufacturer recommendations. Total RNA was extracted from the isolated exosomes as 
described by 12. Equal amount of RNA from each sample was reverse transcribed using the 
TaqMan miRNA Reverse Transcription kit (Applied Biosystems). Since there is no current 
consensus on the use of an internal control for real-time PCR analysis of plasma exosomes, the 
expression of miR-1245 in these fractions relative to RNA U6 and RNA 18S, which are 
expressed in blood exosomes 12 was determined using qRT-PCR as described above.  
 
Reporter gene assays 
A segment of the 3’UTR of the NKG2D gene was amplified by the polymerase chain reaction 
(PCR) from the cDNA of a healthy individual. The PCR was performed with forward 
5’-ATTGGATCCAGATGATCAACCATCTCAATA-3’ and reverse 
5’-ATTGGATCCGCATGAGACTCAAGATTCTAT-3’ primers. The products, which 
encompass nucleotides 816 to 1575 in GenBank accession no. NM_007360.2 and contain 
BamHI sites at both the 5’ and 3’ ends, were digested with BamHI. The resultant fragments 
were sub cloned into BamHI-digested pGL3-Promoter (Promega), in which the simian virus 40 
promoter was replaced with the herpes simplex virus thymidine kinase promoter derived from 
DOI: 10.3324/haematol.2011.058529
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pRL-TK (Promega), to generate pGL3-NKG2D-3’UTR. The correct orientation and nucleotide 
sequences of the inserted 3’UTRs in the plasmid was confirmed by DNA sequencing. A reporter 
plasmid lacking the miR-1245 target site was generated by overlapping PCR as described 
previously 13 using the pGL3-NKG2D-3’UTR as template. The resultant mutant plasmid, 
pGL3-NKG2D-3’UTR-△16, designated hereafter as 3’UTR-mut, has a 16-bp deletion 
(5’-AGGCCAGCAGATCAC/GT-3’), which correspond to the miR-1245 target site. Equimolar 
amounts of each reporter plasmid construct (pGL3-NKG2D-3’UTR, 3’UTR-mut or 
pGL3-TK-Luc) were transfected into NKL cells using Exfect transfection reagent (Takara Bio, 
Japan), or into HEK cells using lipofectamine (Invitrogen), according to the manufacturer’s 
recommendations. The cells were cotransfected with a renilla reporter plasmid (pRL-TK) with 
transfection of the different constructs always running in parallel to control for transfection 
efficiency. The transfected cells were harvested at 48 hours and the activity of both luciferase 
and renilla were measured using the Dual Luciferase Reporter Assay System following the 
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NK cell transduction with exogenous microRNA-1245 
Fresh NK cells were transduced by lentiviral delivery of a human miR-1245 precursor 
microRNA overexpression construct: PMIRH1245PA-1-SBI; or a negative control construct 
vector (pCDH-CMV-MCS-EF1-copGFP) designated hereafter as miR-1245-vector and 
NC-vector, respectively, following the manufacturer’s recommendations (Systems Biosciences, 
Mountain View, CA) with minor modifications. The plasmids were transfected into the 293FT 
packaging cells with the help of a packaging vector (ViraPower Packaging Mix; Invitrogen) and 
lipofectamine 2000 (Invitrogen) to generate packaged pseudoviral particles. Supernatants 
containing lentivirus particles were harvested, and store at -800C until use. Virus titration was 
performed following the manufacturer recommendations. Lentivirus particles containing 
miR-1245-vector or NC-vector were used to transduce primary NK cells. Since these lentiviral 
delivery vectors encode copGFP as a fluorescent marker, the number of positively transduced 
cells, which was more than 90%, was monitored with the help of inverted fluorescent 
microscopy. In some experiments, lentivirus particles were delivered at increasing amounts to 
determine dose dependent induction of mature miR-1245 in primary NK cells, KHYG-1 and in 
HEK cells by using quantitative RT-PCR. For experiments assess comparative effects on NK 
cells lentivirus particles were delivered at a MOI of 50, corresponding to the transducing units 
DOI: 10.3324/haematol.2011.058529
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of 50 X 106/mL. The cells were harvested 48 hours after transduction and separated into two 
aliquots. One aliquot was used for functional assays and the other for assessing the NKG2D 
expression by flow cytometry and quantitative RT-PCR.  
 
Establishment of miR-1245 overexpressing cell lines 
NK cell sub-lines overexpressing miR-1245 derived from NK-92 and KHYG-1 cells were 
established by lentiviral delivery of human miR-1245 Precursor microRNA overexpression 
construct. The lentivirus particles were delivered at a MOI of 50, corresponding to the 
transducing units of 50x106/mL. The effective overexpression of miR-1245 was confirmed by 
quantitative RT-PCR.  
 
Construction of shRNA miR-1245 lentivirus delivery system 
A target sequence of the mature human miR-1245 was inserted in the pENTR/U6 BLOCK-iT 
entry vector (Invitrogen) to generate a shRNA-miR-1245. The plasmid construct was designed 
using the BLOCK-iT RNAi Designer which was obtained from Invitrogen's website. Briefly, 
the annealed oligonucleotides: top strand Oligo;   
5’-CACCGAAGTGATCTAAAGGCCTACACGAATGTAGGCCTTTAGATCA CTT-3’ and 
bottom strand Oligo 5’-AAAAAAGTGATCTAAAGGCCTACATTCGTGTAG 
DOI: 10.3324/haematol.2011.058529
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GCCTTTAGATCACTTC -3’ were inserted into pENTR/U6 vector to generate 
pENTR/miR-1245-shRNA. Stable miR-1245-deficient NK cells were established using the 
BLOCK-iT Lentiviral RNAi Expression System (Invitrogen) according to the manufacturer’s 
recommendations. A recombination reaction using LR clonase was done to transfer the 
pENTR/miR-1245-shRNA or the negative control pENTR/U6-GW/lacZshRNA cassette into the 
pLenti6/BLOCK-iT-DEST (Invitrogen) to construct pLenti6/Block-iT 
pENTR/miR-1245-shRNA (designated thereafter anti-miR-1245) or pLenti6/Block-iT 
pENTR/U6-GW/lacZshRNA (designated thereafter shRNA-NC). These plasmids were 
transfected into the 293FT packaging cells with the help of the packaging vector ViraPower 
Packaging Mix and lipofectamine 2000 (Invitrogen). Culture supernatants containing lentivirus, 
collected 48 hours after transfection, were titrated following the manufacturer recommendations 
and stored at −80°C until use. KHYG-1 cells were transduced with lentivirus at a MOI of 100, 
corresponding to the transducing units of 100 X 106/mL at 37°C overnight. Four days after 
transduction, the cells were selected in blasticidin for three weeks and thereafter were 
sub-cloned by limiting dilution. Seven blasticidin-resistant clones (anti-miR-1245, five clones 




  15 
 
Transfection with a synthetic inhibitor of miR-1245  
A synthetic miR-1245 inhibitor, anti-has-miR-1245 (catalog # MIN0005897), and a miScript 
Inhibitor Negative Control (Catalog # 1027271) anti-microRNA-NC) designated hereafter as 
antago-miR-1245 and antago-NC respectively, were obtained from Qiagen. These synthetic 
antagonists were used to transfect cultured NK cells. The transfection reactions were carried out 
in triplicate using the Hiperfect reagent (Qiagen) following the manufacturer’s 
recommendations. The transfection efficiency was monitored by cotransfecting the cells with a 
GFP-expressing plasmid and cells were examined by flow cytometry and under a fluorescence 
microscope. Twenty-four hours after transfection, the cells were screened for NKG2D 
expression and were used for functional assays. The effective inhibition of the microRNA was 
monitored measuring by measuring mature miR-1245 expression in the transfected cells 
cultured in the presence or absence of TGF-β1. 
 
Measurement of cytokine and Granzyme B secretion 
Primary NK cells (2 × 106/ml) transduced with lentiviral miR-1245 or NC-vector were 
suspended in RPMI 1640 + 10% FBS and 50 U/ml IL-2 and cultured for 48 hours in 96 wells 
plates coated with a mixture composed of 5 µg/ml each of the following recombinant human 
NKG2D ligands: Fc chimeras, MICA, ULBP1 and ULBP2 (R&D Systems) or with human IgG. 
DOI: 10.3324/haematol.2011.058529
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Some cells were cultured in the presence of IL-2 alone. In some experiments, the NK cells lines, 
NKL and KHYG-1, overexpressing miR-1245 or their corresponding wild type counterparts, or 
KHYG-1 cells with miR-1245 KO (all at 1× 106/ml) were cultured for 48 hours in NKG2D 
ligands-coated 96 well plates as described above. The levels of TNF-α, IFN-γ and Granzyme B 
in the culture supernatants were determined by an enzyme-linked immunosorbent assay specific 
for TNF-α, IFN-γ and Granzyme B respectively (ELISA; Mabtech Nacka Strand Sweden) 
following the manufacturer’s recommendations.  
 
Induction of NKG2D ligands on leukemia cells 
To induce the expression of NKG2D-L, the OUN-1 leukemia cells were cultured for 24 hours in 
the presence or absence of 200 µg/ml of valproic acid (VPA), as described in a previous report9. 
The effective induction of the expression of the NKG2D ligands, MICA/B and ULBP-2, in this 
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Cytotoxicity assay 
The cytotoxic activity of NK cells was measured with the LDH Non-Radioactive Cytotoxicity 
Assay (Roche Applied Science) described 14 with minor modifications. The OUN-1 cells were 
harvested as target cells and pre-incubated with 200 µg/mL of valproic acid (VPA) or vehicle 
for 24 hours. In the blocking experiments, the effector cells were incubated with 5 µg of mouse 
anti-NKG2D monoclonal antibodies (mAbs) or an equal amount of isotype control antibodies 
(both from R&D systems) for 30 min at 37°C before their incubation with the target cells. The 
target cells were then placed in the wells of a 96 well plate, and the effector cells (either NK cell 
lines or primary NK cells) were added to each assay well at the indicated concentrations, and 
were incubated at 37°C for 4 hours. The supernatants were then harvested and tested according 
to the manufacturer’s instructions.  
 The effector cells were co-incubated with target cells at a 5:1 effector: target ratio (E: T). 
These ratios were chosen after preliminary optimization experiments. The results are presented 
as the median values from several individuals with each individual tested in triplicate assays for 
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Statistical analysis 
All data are reported as the means ± S.E. when comparisons were made between two different 
groups, statistical significance was determined using Student’s t-test. The statistical significance 
of multiple comparisons was determined using a one-way analysis of variance. The data were 
considered statistically significant when p≤0.05. All statistical analyses were performed using 
the GraphPad Prism software package (San Diego, USA). 
 
Results 
Identification of miR-1245 as a potential negative regulator of NKG2D in NK cells  
Estimated to regulate more than 30% of all human genes, microRNAs have emerged as 
important regulators of gene expression 15. Since NKG2D is a powerful receptor modulated by 
numerous factors, many of which are known to induce changes in microRNA expression 16, we 
hypothesized that the 3’UTR of the NKG2D gene may contain target sites for microRNAs. To 
test this hypothesis, we first screened potential conserved microRNAs targeting the 3’UTR of 
the NKG2D gene by using computational prediction tools. Three different online algorithms, 
TargetScan 7, miTarget 17 and MicroSniper 18 were used to demonstrate that the NKG2D 3’UTR 
contains a conserved region which represents a putative target site for the miR-1245 (Fig. 1A). 
The RNA hybrid software program, which is a computer alignment model based on the 
DOI: 10.3324/haematol.2011.058529
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prediction of the minimal free energy of hybridization 19, further predicted the interaction of 
NKG2D 3’UTR with miR-1245 (Fig. 1B). Next, the endogenous expression of miR-1245 was 
assessed in NK cells to determine the functional significance of the predicted miR-1245 binding 
site in the 3’UTR of NKG2D gene. Quantitative RT-PCR revealed that miR-1245 is expressed 
in fresh NK cells and was also detected at slightly higher levels in cultured NK cells (Fig. 1C). 
Variable levels of mature miR-1245 were also detected in the four NK cell lines tested (Fig. 
1D). Since exosomes from serum samples have been reported to contain functional microRNAs 
11, 20, the expression of miR-1245 was examined in the exosomes from the plasma of patients 
with hematological malignancies or from healthy donors. While miR-1245 was undetectable in 
the plasma exosomes of seven healthy individuals, the exosomes of three out of seven patients 
with Non-Hodgkin lymphoma (NHL) and two out of three patients with acute myelogenous 
leukemia (AML)/myelodysplastic syndrome (MDS) contained abundant levels of miR-1245 
(Fig. 1E), thus substantiating the biological relevance of this novel micro RNA. 
 
Interaction of miR-1245 with the 3’UTR of NKG2D gene 
A luciferase reporter assay was used to directly assess whether the 3’UTR region of NKG2D 
interacts with miR-1245. A fragment of the 3’UTR region of NKG2D was inserted downstream 
from the luciferase open reading frame of the luciferase reporter vector pGL3-TK-Luc and the 
DOI: 10.3324/haematol.2011.058529
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resultant construct was transfected into either stable miR-1245 overexpressing NKL cells or 
their WT counterparts. The presence of NKG2D 3’UTR fragment in the reporter vector 
suppressed the luciferase activity in NKL cells but this effect was significantly higher in cells 
overexpressing miR-1245 (80% luciferase repression) in comparison to that on the WT cells 
(44% luciferase repression) (Figure 2A). The forced expression of miR-1245 in HEK cells 
resulted in a higher repression of luciferase activity induced by the NKG2D 3’UTR construct as 
well (Figure 2B). Remarkably, when the cells were transfected with a mutant reporter plasmid, 
which included a deletion of the microRNA-1245 target sequence region, there was a significant 
decrease in the repression of luciferase activity induced by the NKG2D 3’UTR fragment, which 
completely abolished the increased repression induced by ectopic miR-1245 expression. As 
expected, there were no differences in the luciferase activity in either the miR-1245 
overexpressing cells, or in the WT cells transfected with the pGL3-TK-Luc vector (without 
NKG2D 3’UTR fragments). Taken together, these results indicate that the microRNA-1245 
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Inducible overexpression of miR-1245 in NK cells 
To investigate the potential modulation of endogenous miR-1245 expression in NK cells, we 
first examined the expression of the primary gene transcript of miR-1245, pri-miR-1245, which 
is the starting point in the biogenesis of mature miR-1245. Freshly isolated or activated NK 
cells (Figure 3A) and NK cell lines (Figure 3B) invariably expressed high levels of 
pri-miR-1245 that appeared to be higher than the level of mature miR-1245, suggesting that 
mature miR-1245 may be highly inducible. TGF-β1 was thought as a candidate for miR-1245 
modulation since it is a negative regulator of NKG2D expression 21, 22 and TGF-β1 signals 
upregulate other microRNAs 10, 23. Primary NK cells or NK cell lines were treated with TGF-β1 
and the miR-1245 expression was examined. A quantitative RT-PCR analysis revealed that 
TGF-β1 treatment of primary NK cells induced a consistent and dose-dependent upregulation of 
the mature miR-1245 level (Figure 3C). Of note, TGF-β1 treatment did not augment the 
expression of pri-miR-1245. NK cell lines treated with TGF-β1 also had upregulated mature 
miR-1245 levels (Figure 3D). To investigate whether the TGF-β1-mediated inducible 
overexpression of miR-1245 occurs at the transcriptional or post-transcriptional level, the 
time-based kinetic accumulation of pri-miR-1245 and mature miR-1245 in response to TGF-β1 
treatment was examined in the fresh NK cells derived from 7 individuals. As shown in Figure 
3E, the mature miR-1245 levels started increasing at 8 hours and peaked at 16 hours after 
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starting the TGF-β1 treatment. Conversely, no significant changes in the expression of 
pri-miR-1245 were detected. These results suggest that the TGF-β1-induced miR-1245 
overexpression occurs at the post-transcriptional processing level. The effect of other cytokines 
on the expression of miR-1245 was investigated. While the treatment of NK cells with IL-2 or 
IFNγ had no significant effects on mature or pri-miR1245 levels, IL-15, which is a potent 
inducer of NKG2D expression, decreased the expression of mature miR1245 by 20 fold in NK 
cells (Figure 3F). A dose dependent inhibition of mature miR-1245 by IL-15 further 
confirmed this finding (Online supplementary Figure 1).   
 
Effect of exogenous miR-1245 on NKG2D expression in NK cells       
To investigate the effect of miR-1245 on the expression of NKG2D receptor on NK cells fresh 
NK cells were transduced with a miR-1245 precursor vector (miR-1245-vector) or a negative 
control vector (NC-vector) using a lentiviral delivery system and the NKG2D receptor levels 
were examined after transduction using flow cytometry. Effective overexpression of mature 
miR-1245 levels that were dependent on the amount of lentivirus particles transduced was 
achieved in primary NK cells (Figure 4A) and in NK cell lines, KHYG-1 cells (Figure 4B) 
and HEK cells (Figure 4C), as confirmed by qRT-PCR. The mature miR-1245 levels in NK 
cells transduced with a MOI of 50 were equivalent to those induced by treatment with 10 ng/ml 
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of TGF-β1 for 16 hours, and was achieved in NK cells transduced with miR-1245-vector. The 
overexpression of mature miR-1245 in NK cells resulted in a consistent downregulation of the 
NKG2D receptor. (Figure 4D and 4E). 
 The overexpression of miR-1245 in primary NK cells did not reduce the expression of 
other activator receptors including NKp30, NKp44 and NKp46 in primary NK cells indicating 
the specificity of miR-1245 in the NKG2D downregulation (Online Supplementary Figure 2). 
Next, quantitative real time PCR was used to measure NKG2D mRNA levels in NK cells 
transduced with miR-1245 in order to identify the suppressive mechanism used by this 
particular microRNA, since microRNAs can suppress gene expression by inhibiting translation 
or by inducing mRNA degradation. There were significantly lower levels of NKG2D transcripts 
in NK cells transduced with the miR-1245-vector in comparison with the untreated cells or the 
NC-vector transduced cells (P<0.05) (Figure 4F) 
 To substantiate whether the downregulation of NKG2D by miR-1245 in NK cells has 
functional significance, the NKG2D-mediated effector functions were assessed in NK cells 
overexpressing miR-1245. Previous reports have demonstrated that in vitro engagement of the 
NKG2D receptor by recombinant NKG2D ligands is sufficient to deliver activator signals 
leading to cytokine release from the NK cells 24. To examine whether the NKG2D 
downregulation induced by miR-1245 has functional implications, primary NK cells from 7 
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healthy donors transduced with the miR-1245-vector, and their counterparts transduced with the 
NC-vector, were cultured in plates coated with a mixture of recombinant NKG2D-Ls or on 
plates coated with mouse IgG, and the levels of TNF-α in the cell culture supernatants were 
measured by an ELISA. The NK cells overexpressing miR-1245 secreted significantly lower 
levels of TNF-α in response to NKG2D engagement with recombinant NKG2D ligands 
compared to the NK cells transduced with the NC-vector (Figure 4G). Consistent with these 
results of the cytokine secretion assay, the miR-1245 overexpressing NK cells displayed 
significantly lower cytotoxicity against the myeloid leukemia OUN-1 cells treated with VPA, an 
inducer of NKG2D-Ls in this cell line (Online Supplementary Figure 3), compared with the NK 
cells transduced with NC-vector (Figure 4H). There was no difference in the killing effect 
between NK cells and miR-1245-transduced NK cells when the target cells were pretreated with 
vehicle alone, or when the effector NK cells were pretreated with anti-NKG2D mAbs, thus 
suggesting that this effect was ligand-dependent. Taken together, these results suggest that the 
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NK cell lines overexpressing miR-1245 downregulate NKG2D expression 
NK cells sub-lines derived from NK-92 and KYHG-1 cells lines were established by lentivirus 
delivery of the miR-1245-vector. The effective overexpression of miR-1245 in NK cell lines 
resulted in a significant decrease in the cell surface NKG2D expression in KHYG-1 and NK-92 
cells (Figure 5A and 5B) and a reduced NKG2D transcript (Figure 5C), thus indicating 
miR-1245 to be a negative regulator of NKG2D expression. The overexpression of miR-1245 in 
these cell lines was not associated with a reduction in the expression of other activator receptors 
(Supplementary Fig.  4A and 4B). The KHYG-1 (Figure 5D) and NK-92 cells (Figure 
5E)  overexpressing miR-1245 secreted significantly lower levels of IFN-γ in response to 
NKG2D receptor engagement by NKG2D-Ls. Consistent with IFN-γ secretion assay, KHYG-1 
(Figure 5F) and NK-92 cells (Figure 5G) overexpressing miR-1245 secreted significantly 
lower levels of granzyme B. We were unable to test the effect of miR-1245 overexpression on 
the secretion of TNF-α by NK cell lines because this cytokine was undetectable in the 
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Knocking down miR-1245 in NK cells resulted in higher NKG2D expression and relative 
resistance to TGF-β1 effect 
miR-1245 deficient NK cell lines were established by lentivirus delivery of the anti-miR-1245 
to substantiate the role of miR-1245 in the regulation of NKG2D expression in NK cells. A 
KYHG-1 clone was identified, in which effective miR-1245 knockdown was consistently 
achieved as demonstrated by quantitative RT-PCR. In contrast to their WT counterpart or in 
clones transduced with shRNA-NC, these cells do not express miR-1245 even in the presence of 
TGF-β1 treatment (Supplementary Fig 5). Interestingly miR-1245 5KO cells express higher 
levels of NKG2D receptor at both protein (Fig. 6A) and transcript levels (Fig. 6B). In 
addition, although TGF-β1 treatment also resulted in the downregulation of NKG2D receptor in 
miR-1245 5KO cells, this effect was less notable than in WT cells (Fig. 6C) or in those cells 
transduced with shRNA-NC (data not shown). Moreover, miR-1245 5KO cells secreted higher 
levels of IFN-γ in response to NKG2D receptor engagement by NKG2D-Ls compared to 
KYHG-1 cells transduced with shRNA-NC or with their WT counterpart (supplementary 
Fig.  6) . These results suggest that NKG2D downregulation induced by TGF-β1 in NK cells 
involves miR-1245 induction. 
 To address whether the effects of knocking down miR-1245 are also observed in primary 
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NK cells, cultured NK cells from 4 healthy individuals were transiently transfected with a 
synthetic antagonist of miR-1245 or a negative control antago-NC. The 
antago-miR-1245-transfected cells upregulated NKG2D receptor (Fig. 6D ) and were less 
sensitive to the effects of TGF-β1 treatment on the downregulation of NKG2D expression 
compared to their antago-NC-transfected counterparts (Fig. 6E). 
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Normal cells require a protective mechanism against NKG2D receptor overactivation to prevent 
self-attack, since NKG2D is implicated in certain autoimmune conditions 25. This study has 
identified a novel mechanism for the modulation of NKG2D gene expression in NK cells. 
Several in vitro approaches demonstrated that miR-1245 interacts with the 3’UTR region of 
NKG2D, and that this interaction resulted in the downregulation in NKG2D expression in NK 
cells, thus leading to an impairment in NKG2D-mediated immune functions, including less 
effective cytotoxicity and lower cytokine secretion.  
 One question remains with regard to how miR-1245 contributes to regulating the 
expression of NKG2D in vivo. The constitutive expression of miR-1245 in NK cells suggests 
that it may represent an endogenous autoregulatory mechanism to maintain NKG2D expression 
at physiological levels. NK cells are a pivotal source of endogenous TGF-β1, and this 
immunosuppressive cytokine secreted from NK cells represses NK cell functions, including the 
downregulation of the NKG2D expression, in a paracrine/autocrine manner 21, 26, 27, thus 
indicating that TGF-β1 plays an important role as a negative feedback to prevent 
overstimulation of NK cell functions. The current findings suggest that miR-1245 induction 
may therefore represent one of the downstream mechanisms by which TGF-β1 exerts such 
negative feedback for controlling NK cells activation.  
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 NKG2D receptor plays a relevant role in tumor immunosurveillance and cancer cells use 
several mechanisms to escape NKG2D-mediated cytotoxicity including the downregulation of 
NKG2D ligands on their surface, the release of soluble NKG2D ligands, to induce NKG2D 
silencing and the secretion of immunosuppressive cytokines. Indeed various cancer cells 
produce TGF-β1, which impairs NK cell functions in cancer patients, leading to stimulation of 
tumor growth 21, 22, 28 and TGF-β1 released by tumor arising cells has been suggested to 
influence immunosurveillance and the tumor microenvironment represent an important source 
of TGF-β1 impairing NKG2D-mediated functions 29. The present study suggests the 
involvement of miR-1245 in the mechanism(s) whereby the TGF-β1 produced in cancer patients 
may modulate NK cell functions. It is also conceivable that tumor cells might secrete miR-1245 
and use this as a way to downregulate NKG2D expression in order to escape NK cell-mediate 
killing. Although it is highly speculative, the release of microRNAs through exosomes may 
provide a route by which tumor cells may deliver functional miR-1245 to impair NKG2D 
expression. In fact, tumor-derived exosomes have been reported to downregulate NKG2D 
expression in NK cells 22. Our finding that miR-1245 was detectable in exosomes of some 
patients with NHL as well as in AML patients may support this hypothesis, although we were 
unable to investigate the possible correlation between miR-1245 expression in exosomes and 
NKG2D levels, since no NK cells from those patients were available for this study. Further 
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studies on the functional relevance of exosome derived miR-1245 are thus warranted. 
 The mature miR-1245 overexpression induced by TGF-β1 in NK cells occurs at post 
transcriptional level which is consistent with the mechanism by which TGF-β1 induces mature 
miR-21 in human vascular smooth muscle cells 10, 23. The regulation of miR-21 biogenesis 
involves the recruitment of TGF-β1–ligand specific SMAD signal transducer to members of the 
DROSHA microprocessor complex which facilitate the processing of primary transcript into 
pre-microRNA 30. 
 The overexpression of miR-1245 reduced the NKG2D expression at both the protein (Fig. 
4E) and mRNA (Fig. 4F) level in primary NK cells, thus suggesting that miR-1245 suppresses 
the expression of NKG2D through mRNA degradation, which is consistent with a recent report 
showing that decreasing the target mRNA is the main mechanism by which mammalian 
microRNA regulate gene expression 31. However, the reduction of the expression of NKG2D 
appears to be greater at the protein level than the reduction at the mRNA level. Accordingly, in 
addition to mRNA degradation, miR-1245 could cause translational repression of mRNA, which 
may be supported by previous reports that microRNA reduces translation initiation32 and 
increases ribosome drop-off 33. 
 The present study did not investigate miR-1245 expression in different NK cell subsets 
such as CD56 bright and CD56 dim. However NK cells isolated from healthy individuals were 
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more than 95% CD16 positive, thus suggesting that the vast majority of the NK cells were 
CD56dim and responsive for cytolytic activity and target killing34. Elucidating the functional 
roles of miR1245 in CD56 bright CD16 negative NK cells, which are the main source of 
cytokine production, is a promising challenge. 
 In conclusion, the current study has identified miR-1245 as a novel regulator of NKG2D 
expression that acts by targeting the 3’UTR region of the NKG2D gene. TGF-β1, which is a 
potent NKG2D suppressor in NK cells, post-transcriptionally enhanced the expression of 
mature miR-1245, leading to the downregulation of the NKG2D receptor. There is a large 
amount of evidence to support the role of NKG2D in tumor immunosurveillance and 
progression. Although several clinical trials of TGF-β1 antagonists for cancer treatment are 
underway 35, the main concern is that TGF-β1 antagonists could enhance the proliferation of 
tumor cells, which may counterbalance their potential therapeutic benefits on 
immmunomodulation 36. A recent report has shown that the processing of pri-microRNA could 
be selectively blocked 37. Therefore, miR-1245 could be a promising target for tumor 
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Figure 1. Identification of miR-1245 as a potential negative regulator of NKG2D in NK cells 
(A) A schematic representation of the interaction between miR-1245 and its target site in the 
3’UTR region of NKG2D mRNA. (B) Computational modeling showed the hybridization of 
miR-1245 and the 3’UTR region of NKG2D mRNA, (mfe) represents the calculated minimal 
free energy. (C) The mature miR-1245 expression in fresh or activated primary NK cells was 
measured by quantitative RT-PCR and normalized to U6B RNA. The data are the means ± 
S.E.M. (n= 13). (D) The expression of mature miR-1245 normalized to that of U6B RNA in NK 
cells lines YT, KYHG-1, NK92 and NKL. (E) The expression of mature miR-1245 in exosomes 
isolated from plasma samples of patients with NHL (n=7), AML/MDS (n=3) and from 7 healthy 
donors. 
 
Figure 2. The interaction of miR-1245 with the NKG2D gene 3’UTR 
(A) NKL cells or (B) HEK cells overexpressing miR-1245, or their wild type (WT) counterparts, 
were transfected with a luciferase expression vector (pGL3-TK-Luc), or with constructs 
including the NKG2D 3’UTR (NKG2D-3’ UTR-Luc) or with a luciferase expression vector that 
included the NKG2D 3’UTR with a 16 bp deletion of the miR-1245 targeting site (3’ 
UTR-mut). The firefly luciferase activities measured 48 hours after transfection were 
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normalized to the Renilla luciferase expression and the mean activities ± S.E.M. from three 
independent experiments are shown.  
 
Figure 3. Post-transcriptional regulation of mature miR-1245 biogenesis in NK cells by 
TGF-β1. 
(A) The expression of the primary gene transcripts (pri-miR-1245) in fresh and cultured NK 
cells normalized to GAPDH. The data are the mean values +/- S.E.M. from measurements in 7 
donors. (B) The expression of pri-miR-1245 normalized to GAPDH in the NK cell lines YT, 
NK92, KYHG-1, and NKL. (C) The expression of pri-miR-1245 and mature miR-1245 in 
primary NK cells treated with various concentrations of TGF-β1 for 24 hours (n=7). (D) The 
expression of mature miR-1245 in NK cell lines after treatment with TGF-β1 (2.5 or 10 ng/ml) 
for 24 hours. The error bars in C and D show the ± S.E.M. from 3 independent experiments, 
each measured in duplicate. (E) The time course of pri-miR-1245 and mature miR-1245 
expression in primary NK cells after treatment with TGF-β1 (10 ng/ml) (n=7). The data are the 
means ± S.E.M. from 3 independent experiments, each measured in duplicate. (F) The 
expression of pri-miR-1245 (open bar) and mature miR-1245 (closed bar) in primary NK cells 
treated with IL-2 (150 U/ml), IL-15 (50 ng/ml) or IFN γ for 24 hours. The error bars show the ± 
S.E.M. from 3 independent experiments, each measured in duplicate 
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Figure 4. Exogenous miR-1245 decreases the NKG2D expression in NK cells. 
The relative expression of mature miR-1245 in (A) fresh NK cells derived from 5 donors or in 
(B) KHYG-1 or (C) HEK cells transduced with increasing amounts of lentiviral particles 
containing a human miR-1245 precursor vector (miR-1245-vector, closed bar) or a negative 
control vector (NC-vector, open bar). The data are the means ± S.E.M. from 3 independent 
experiments. (D and E) The cell surface expression of NKG2D on the miR-1245-transduced 
primary NK cells. Fresh NK cells were left untreated or were transduced at a MOI 50 with the 
miR-1245-vector or with the NC-vector for 48 hours, and the surface expression of NKG2D 
was examined by flow cytometry. The panel D shows representative results of cells stained with 
anti-NKG2D (black line filled histograms) or with the isotype antibody (open histogram). The 
summarized data from 12 donors are shown in the panel E. (F) Fresh NK cells were transduced 
as in the panels D and E, and the NKG2D mRNA levels were measured by quantitative 
RT-PCR 24 hours after transduction. The relative results normalized to U6b RNA are expressed 
as the percentage of the mRNA compared to that for the control conditions (untreated cells). (G) 
Fresh NK cells transduced with the miR-1245-vector or with the NC-vector (n=7) were 
harvested and cultured for another 48 hours in 96 well plates coated with a mixture of 3 
recombinant NKG2D-Ls (MICA, ULBP-1 and ULBP-2; closed bar) or control IgG (gray bar). 
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The levels of TNF-α in the culture supernatants were determined using an ELISA. (H) Fresh 
NK cells treated as in the panel G were left untreated (medium), or were pre-incubated for 30 
min with an anti-NKG2D antibody or with an isotype antibody, and then assessed for their 
cytotoxicity against OUN-1 leukemia cells which had been pre-treated with or without 
200 µg/mL VPA for 24 hours. The summarized data from 7 donors (effector: target ratio, 5:1) 
are shown. The data are the means ± S.E.M. from 3 independent experiments. *indicates 
p<0.05. 
 
Figure 5. Downregulation of the NKG2D receptor in NK cell lines stably overexpressing 
miR-1245. 
NK cell lines, NK92 andKHYG1 overexpressing miR-1245 were established by lentiviral 
delivery of a vector containing the miR-1245 precursor. (A) miR-1245 overexpressing cells or 
those transduced with a negative control vector were examined for NKG2D expression by flow 
cytometry. The filled histograms represent the cells transduced with negative control vector, 
empty histograms are cells transduced with the miR-1245-vector, and dashed line histograms are 
cells stained with the isotype antibody. A representative figure showing the results of three 
independent experiments is shown. The panel B shows summarized results of three independent 
experiments for each cell line (open bar, NC-Vector; closed bar, miR-1245-Vector). (C) Total 
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RNA was extracted from the above-described cells, and the normalized levels of the NKG2D 
transcript were measured by quantitative RT-PCR (gray bar, NC-Vector; closed bar, 
miR-1245-Vector). (D) The KHYG1 cells and (E) NK-92 cells overexpressing miR-1245 or their 
counterparts transduced with NC-vector were cultured for 48 hours in 96 well plates coated with 
recombinant NKG2D-Ls (MICA, ULBP-1 and ULBP-2). The levels of IFN-γ in the culture 
supernatants were determined using an ELISA. (F) The KHYG1 cells and (G) NKL cell 
overexpressing miR-1245 or their counterparts transduced with NC-vector were cultured as in (C) 
and the levels of granzyme B in the culture supernatants were determined using an ELISA. The 
data are the means ± S.E.M. from 3 independent experiments. *indicates p<0.05. 
 
Figure 6. Knockdown of miR-1245 increases the expression of NKG2D in NK cells, and 
renders the cells less sensitive to TGF-β1. 
(A) KYHG-1 cells were examined by flow cytometry for NKG2D expression. The filled 
histogram represents the shRNA-NC-transduced KHYG-1 cells stained with the anti-NKG2D 
antibody. In the open histogram, the solid line shows the data from the miR-1245 5KO 
KHYG-1 cells stained with the anti-NKG2D antibody, and in the open histogram, the dotted 
line indicates cells stained with the isotype antibody. A representative figure from three 
independent experiments is shown. (B) Total RNA was extracted, and the levels of NKG2D 
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mRNA normalized to the levels of GAPDH were measured by RT-PCR. The figure shows the 
means ± S.E.M. from three independent experiments. (C) The miR-1245 5KO KHYG-1 cells or 
WT KHYG-1 cells were cultured for 48 hours in the presence or absence of TGF-β1, and their 
NKG2D expression levels were examined by flow cytometry. The filled histogram represents 
untreated cells, the green histograms represent cells treated with TGF-β1 (5 ng/ml), the red 
histograms represent cells treated with TGF-β1 (10 ng/ml) and the blue histograms with the 
dotted line represent cells stained with the isotype antibody. A representative figure from the 
data obtained from three independent experiments is shown. (D) Cultured NK cells were left 
untreated or were transfected with antago-miR-1245 or antago-NC, and 48 hours later, their 
NKG2D expression levels were examined by flow cytometry. The filled histogram represents 
cells transfected with antago-miR-1245 or antago-NC, the open histogram with solid lines 
represents untreated cells, and the open histograms with the dotted line represent cells stained 
with the isotype antibody. A representative figure from the data obtained from three 
independent experiments is shown. (E) Primary NK cells were transfected as in the panel D. 
Twenty-four hours later, they were treated with TGF-β1 (10 ng/ml) and cultured for other 24 
hours, and their NKG2D expression levels were examined by flow cytometry. Summarized data 
for the NK cells from 5 donors is shown. The data are the means ± S.E.M. from 3 independent 
experiments.  
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Online Supplementary information 
 
 
Online Supplementary Figure 1 The expression of miR-1245 and pri-miR-1245 in NK cells 
response to stimulation with IL-15. Primary NK cells were cultured for 24 hrs with the indicated 
concentrations of IL-15. Total RNA was extracted and the levels of mature miR-1245 and 
pri-miR-1245 were measured by RT-PCR. The data are the means ± S.E.M. from 3 independent 
experiments using cells from healthy donors (n=3).   
 
Online Supplementary Figure 2 The expression of activator receptors on NK cells transduced 
with miR-1245 precursor or a NC-Vector or on their WT counterpart assessed by Flow 
cytometry. A representative figure using cells from the same donor is shown.  
 
Online Supplementary Figure 3 The expression of the NKG2D ligands ULBP-2 and MICA/B 
on the surface OUN-1 cells cultured for 24 hours in the presence or absence of valproic acid.   
 
Online Supplementary Figure 4. The expression of activator receptors on KYHG-1 cells (A) 
or NK-92 cells (B)  transduced with miR-1245-Vector or a NC-Vector or on their WT 
counterpart. A representative figure from each cell line is shown. 
 
Online Supplementary Figure 5 The miR-1245 5KO KHYG-1 cells or their counterparts 
transduced with shRNA-NC, or the WT KHYG-1 cells, were cultured for 24 hours in the 
presence or absence of TGF-β1 (10 ng/ml), and the levels of mature miR-1245 normalized to 
that of U6b RNA were measured by quantitative RT-PCR. The data are the means ± S.E.M. 
from 3 independent experiments. 
 
Online Supplementary Figure 6. The miR-1245 5KO KHYG-1 cells or their counterparts 
transduced with shRNA-NC, or the WT KHYG-1 cells, were cultured for 48 hours in 96 well 
plates coated with recombinant NKG2D-Ls. The levels of IFN-γ in the culture supernatants 
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